Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0250


Cancer Biomarkers: Pitfalls with traditional research and novel integrated genome analysis opportunities.

George Zografos MD, PhD.

Affiliation: Head of the Breast Unit, Head of 1st Department of Propaedeutic Surgery, University of Athens, Greece.

Tel: +306932524836


Since there is no abstract available we provide the first paragraph.
Most of “omics” studies-based prognostic and predictive biomarkers have limited practical medical utility particular in clinical management of cancer. To prevent false reports, certain diseases, the US National Cancer Institute (NCI) released a draft list of 29 criteria, such as documenting where specimens came from and ensuring experiments can be properly replicated . Now researchers must address these criteria before receiving NCI funds to run a clinical trial. But even if these criteria are met, there is skepticisism whether robust biomarkers can be produced without deep genome sequencing and integrated genome functional analysis of clinical samples.

(Citation: Gastric & Breast Cancer 2012; 11(4): 236-238)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 October 2012